{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:26:16Z","timestamp":1787293576358,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA) can be managed either by unilateral adrenalectomy (ADX) or pharmacologically with mineralocorticoid receptor antagonists (MRA). Several recent meta-analyses have examined how these treatment modalities affect cardiovascular outcomes in patients with PA. However, the impact of treatment on quality of life (QoL) remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize data from previous studies that have investigated QoL in either medically or surgically treated patients with PA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted in May 2025 in PubMed, Embase and Web of Science. Studies containing data on QoL before and after ADX or MRA were selected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies evaluated QoL after treatment for PA. Most comparative studies reported greater and faster QoL improvement after ADX than with MRA. QoL consistently improved after ADX, whereas results with MRA were variable and less consistent. Patients treated with MRA were older than patients treated with ADX and frequently received low MRA doses. Five studies (259 ADX-treated and 88 MRA-treated patients) were included in a meta-analysis. Baseline QoL did not differ between treatment groups. At 6 months, QoL improved in both groups, with no statistically significant difference between ADX and MRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of PA is associated with improved QoL following both ADX and MRA therapy. Although several studies suggest superior outcomes after adrenalectomy, the meta-analysis did not show a significant difference at 6 months of follow-up. The limited number of patients, short follow-up duration, and potential undertreatment with MRA represent important limitations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02903-6","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:01:08Z","timestamp":1778061668000},"page":"2305-2313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life in primary aldosteronism, medical vs surgical treatment: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Merel","family":"Wever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Gkaniatsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0204-9492","authenticated-orcid":false,"given":"Oskar","family":"Ragnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2903_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12831","volume":"285","author":"WF Young Jr.","year":"2019","unstructured":"Young WF Jr. (2019) Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 285:126\u2013148","journal-title":"J Intern Med"},{"key":"2903_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","volume":"106","author":"TA Williams","year":"2021","unstructured":"Williams TA, Gomez-Sanchez CE, Rainey WE et al (2021) International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 106:42\u201354","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A (2018) Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 6:51\u201359","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2903_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1161\/HYPERTENSIONAHA.123.21895","volume":"80","author":"E Gkaniatsa","year":"2023","unstructured":"Gkaniatsa E, Zverkova Sandstrom T, Rosengren A et al (2023) Mortality in patients with primary aldosteronism: a Swedish nationwide study. Hypertension 80:2601\u20132610","journal-title":"Hypertension"},{"key":"2903_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/ajh\/hpaf029","volume":"38","author":"L Yuan","year":"2025","unstructured":"Yuan L, Li X, Sun F et al (2025) Comparative outcomes of adrenalectomy mineralocorticoid receptor antagonist and percutaneous adrenal ablation for primary aldosteronism: a systematic review and network meta-analysis. Am J Hypertens 38:654\u2013665","journal-title":"Am J Hypertens"},{"key":"2903_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038714","volume":"14","author":"CW Huang","year":"2025","unstructured":"Huang CW, Huang TY, Yang YF, Chang LM, Tu YK, Wu VC, Chen JY (2025) Major adverse cardiovascular events in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a systematic review and meta-analysis. J Am Heart Assoc 14:e038714","journal-title":"J Am Heart Assoc"},{"key":"2903_CR7","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1210\/clinem\/dgad654","volume":"109","author":"S Samnani","year":"2024","unstructured":"Samnani S, Cenzer I, Kline GA et al (2024) Time to benefit of surgery vs targeted medical therapy for patients with primary aldosteronism: a meta-analysis. J Clin Endocrinol Metab 109:e1280\u2013e1289","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13419","volume":"51","author":"F Buffolo","year":"2021","unstructured":"Buffolo F, Cavaglia G, Burrello J et al (2021) Quality of life in primary aldosteronism: a prospective observational study. Eur J Clin Invest 51:e13419","journal-title":"Eur J Clin Invest"},{"key":"2903_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1530\/EC-21-0125","volume":"10","author":"YK Tan","year":"2021","unstructured":"Tan YK, Kwan YH, Teo DCL et al (2021) Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: asian cohort study. Endocr Connect 10:834\u2013844","journal-title":"Endocr Connect"},{"key":"2903_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"Velema M, Dekkers T, Hermus A et al (2018) Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab 103:16\u201324","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR11","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M (2011) Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 96:2904\u20132911","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR12","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab174","volume":"6","author":"A Saiki","year":"2022","unstructured":"Saiki A, Otsuki M, Tamada D, Kitamura T, Mukai K, Yamamoto K, Shimomura I (2022) Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin. J Endocr Soc 6:bvab174","journal-title":"J Endocr Soc"},{"key":"2903_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41440-023-01412-w","volume":"47","author":"Y Yoshida","year":"2024","unstructured":"Yoshida Y, Fujiwara M, Kinoshita M et al (2024) Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res 47:157\u2013167","journal-title":"Hypertens Res"},{"key":"2903_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072585","volume":"13","author":"A Rocca","year":"2023","unstructured":"Rocca A, Gkaniatsa E, Brunese MC et al (2023) Therapeutic outcomes with surgical and medical management for primary aldosteronism: protocol for a systematic review and meta-analysis. BMJ Open 13:e072585","journal-title":"BMJ Open"},{"key":"2903_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210","journal-title":"Syst Rev"},{"key":"2903_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr.","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"2903_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"2903_CR18","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2009-1763","volume":"95","author":"N Sukor","year":"2010","unstructured":"Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M (2010) Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 95:1360\u20131364","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","volume":"46","author":"HE Kunzel","year":"2012","unstructured":"Kunzel HE, Apostolopoulou K, Pallauf A et al (2012) Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res 46:1650\u20131654","journal-title":"J Psychiatr Res"},{"key":"2903_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","volume":"4","author":"T Dekkers","year":"2016","unstructured":"Dekkers T, Prejbisz A, Kool LJS et al (2016) Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol 4:739\u2013746","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2903_CR21","doi-asserted-by":"publisher","first-page":"e2423","DOI":"10.1210\/clinem\/dgab099","volume":"106","author":"P Gendreitzig","year":"2021","unstructured":"Gendreitzig P, Kunzel HE, Adolf C et al (2021) Autonomous cortisol secretion influences psychopathological symptoms in patients with primary aldosteronism. J Clin Endocrinol Metab 106:e2423\u2013e2433","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eprac.2023.10.003","volume":"30","author":"J Yu","year":"2024","unstructured":"Yu J, Xu B, Ma G, Liu Y, Yang Y, Xu J, Sun M (2024) A prospective observational study of factors affecting the change in quality of life in patients with primary aldosteronism after treatment. Endocr Pract 30:19\u201324","journal-title":"Endocr Pract"},{"key":"2903_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/HYPERTENSIONAHA.123.21965","volume":"81","author":"RA Ananda","year":"2024","unstructured":"Ananda RA, Gwini SM, Long KM et al (2024) Diagnostic delay and disease burden in primary aldosteronism: an international patient survey. Hypertension 81:348\u2013360","journal-title":"Hypertension"},{"key":"2903_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/iju.14016","volume":"26","author":"S Ishidoya","year":"2019","unstructured":"Ishidoya S, Kawasaki Y, Namiki S, Morimoto R, Takase K, Ito A (2019) Changes in quality of life after laparoscopic adrenalectomy for patients with primary aldosteronism: prospective 2-year longitudinal cohort study in a Japanese tertiary center. Int J Urol 26:752\u2013753","journal-title":"Int J Urol"},{"key":"2903_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-018-0432-1","volume":"18","author":"M Citton","year":"2019","unstructured":"Citton M, Viel G, Torresan F, Rossi GP, Iacobone M (2019) Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism. BMC Surg 18:105","journal-title":"BMC Surg"},{"key":"2903_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000518165","volume":"107","author":"Y Kawasaki","year":"2023","unstructured":"Kawasaki Y, Ishidoya S, Morimoto R et al (2023) Laparoscopic adrenalectomy is beneficial for the health-related quality of life of older patients with primary aldosteronism. Urol Int 107:186\u2013192","journal-title":"Urol Int"},{"key":"2903_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab020","volume":"5","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Yoshida R, Shibuta K, Ozeki Y, Okamoto M, Gotoh K, Masaki T, Shibata H (2021) Quality of life of primary aldosteronism patients by mineralocorticoid receptor antagonists. J Endocr Soc 5:bvab020","journal-title":"J Endocr Soc"},{"key":"2903_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277902","volume":"17","author":"O Ragnarsson","year":"2022","unstructured":"Ragnarsson O, Muth A, Johannsson G, Gkaniatsa E, Ung EJ, Jakobsson S (2022) Illness perspectives in patients with primary aldosteronism. PLoS ONE 17:e0277902","journal-title":"PLoS ONE"},{"key":"2903_CR29","doi-asserted-by":"crossref","DOI":"10.5888\/pcd19.220062","volume":"19","author":"L Van Wilder","year":"2022","unstructured":"Van Wilder L, Devleesschauwer B, Clays E, Pype P, Vandepitte S, De Smedt D (2022) Polypharmacy and health-related quality of life\/psychological distress among patients with chronic disease. Prev Chronic Dis 19:E50","journal-title":"Prev Chronic Dis"},{"key":"2903_CR30","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s11136-023-03473-3","volume":"32","author":"EA Gebreyohannes","year":"2023","unstructured":"Gebreyohannes EA, Gebresillassie BM, Mulugeta F, Dessu E, Abebe TB (2023) Treatment burden and health-related quality of life of patients with multimorbidity: a cross-sectional study. Qual Life Res 32:3269\u20133277","journal-title":"Qual Life Res"},{"key":"2903_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.123.21910","volume":"81","author":"AF Turcu","year":"2024","unstructured":"Turcu AF, Tezuka Y, Lim JS et al (2024) Multifocal, asymmetric bilateral primary aldosteronism cannot be excluded by strong adrenal vein sampling lateralization: an international retrospective cohort study. Hypertension 81:604\u2013613","journal-title":"Hypertension"},{"key":"2903_CR32","doi-asserted-by":"crossref","unstructured":"Fuld S, Adolf C, Constantinescu G, et al (2026) Improvement of health-related quality of life and mental health after unilateral adrenalectomy for primary aldosteronism. Clin Endocrinol (Oxf)","DOI":"10.1111\/cen.70106"},{"key":"2903_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","volume":"13","author":"J Yang","year":"2025","unstructured":"Yang J, Burrello J, Goi J et al (2025) Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol 13:119\u2013133","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2903_CR34","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR et al (2025) Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 110:2453\u20132495","journal-title":"J Clin Endocrinol Metab"},{"key":"2903_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1055\/s-0043-121706","volume":"49","author":"MS Velema","year":"2017","unstructured":"Velema MS, de Nooijer AH, Burgers VWG, Hermus A, Timmers H, Lenders JWM, Husson O, Deinum J (2017) Health-related quality of life and mental health in primary aldosteronism: a systematic review. Horm Metab Res 49:943\u2013950","journal-title":"Horm Metab Res"},{"key":"2903_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"Williams TA, Lenders JWM, Mulatero P et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5:689\u2013699","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02903-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:51Z","timestamp":1787292531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02903-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2903"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02903-6","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have conflicts of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}